Wu, Xuewei http://orcid.org/0000-0003-1722-2278
Yang, Xiaobao http://orcid.org/0000-0001-5266-7673
Xiong, Yan
Li, Ruitong
Ito, Takahiro
Ahmed, Tamer A.
Karoulia, Zoi
Adamopoulos, Christos
Wang, Hong http://orcid.org/0000-0002-8787-715X
Wang, Li
Xie, Ling
Liu, Jing
Ueberheide, Beatrix
Aaronson, Stuart A.
Chen, Xian
Buchanan, Sean G. http://orcid.org/0000-0002-5215-4672
Sellers, William R. http://orcid.org/0000-0002-3539-9803
Jin, Jian http://orcid.org/0000-0002-2387-3862
Poulikakos, Poulikos I. http://orcid.org/0000-0001-6071-9963
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01CA204314, R01CA240362, R01CA238229, T32CA078207, 1R01CA233626, P30CA196521)
Melanoma Research Alliance
Melanoma Research Foundation
Breast Cancer Alliance
U.S. Department of Defense (W81XWH-19-1-0271)
Article History
Received: 17 July 2020
Accepted: 21 January 2021
First Online: 1 March 2021
Competing interests
: X.W., X.Y., Y.X., T.A., Z.K., J.L., J.J. and P.I.P. hold a patent on CDK4/6-directed degradation (WO/2018/106870). The Jian Jin laboratory received research funds from Celgene Corporation, Levo Therapeutics and Cullgen, Inc. J.J. is an equity shareholder and consultant of Cullgen, Inc. H.W. and S.G.B. are employees of Eli Lilly. All other authors declare no competing interests.